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Background: Cognitive disturbances of chronic cocaine users (CU) have been
repeatedly investigated. However, it is yet unknown how CU using cocaine for cognitive
or social enhancement differ from stimulant-naïve controls and CU that do not have these
motives. More precisely, we assumed that CU with an enhancement motive self-medicate
deficits in specific cognitive abilities, i.e., they use cocaine to enhance their performance in
either social (social motive) or non-social cognitive situations (cognitive motive).
Methods: Forty-two CU were categorized according to their motives for cocaine
consumption into social and non-social motive groups as well as cognitive and non-
cognitive motive groups, respectively. Subsequently, CU motive groups were compared
to 48 stimulant-naïve controls in their social and non-social cognitive functioning applying
a comprehensive neuropsychological test battery.
Results: The social motive group showed deficits in cognitive empathy compared to
controls (Cohen’s d = 0.65) and the non-social motive group (d = 0.60). No mentionable
effects were found for emotional empathy and Theory-of-Mind. Cognitive and non-
cognitive motive groups both showed general cognitive deficits but with different
patterns of impairments compared to controls: the cognitive motive group had deficits
mainly in working memory (d = 0.84) and declarative memory (d = 0.60), whereas the non-
cognitive motive group also had deficits in working memory (d = 0.61) but additionally in
executive functions (d = 0.67). For the domains declarative memory and executive
functions, the respective other CU group displayed intermediate performance.
Conclusions: This study demonstrates that cocaine is partially instrumentalized by CU
with specific enhancement motives to counteract related cognitive impairments.
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INTRODUCTION
It has been consistently demonstrated, that cocaine users (CU)
show broad cognitive impairments spanning from basic
functions such as attention and working memory to more
complex abilities such as executive functions, social cognition,
and social decision-making (1–8). A recent study suggested that
30% of dependent and 12% of recreational users displayed
clinically relevant global cognitive impairment (2). While
dependent users showed the strongest deficits in working
memory and executive functions, recreational users displayed
the strongest effect sizes in attention and memory functions (2).
Regarding social cognition, CU generally show impaired basic
emotion recognition from faces, specifically regarding fear and
anger (9–12). Additionally, dependent and even recreational CU
revealed moderate deficiencies in emotional empathy (4) as well
as in emotion recognition from voices (13). However, only
dependent CU showed impaired mental and emotional
perspective-taking (Theory-of-Mind, ToM) (4). Finally, CU
demonstrated reduced prosocial behavior in social interaction
tasks (3) and were less rewarded by social feedback (14). Notably,
longitudinal data recently suggested that both cognitive and
social cognitive impairments are partially drug-induced and
can be improved to a certain extent with decreasing cocaine
consumption (15, 16).
Given these relatively broad cognitive deficits and the
potential of cocaine to boost cognitive functions acutely (17),
one might assume that at least some CU instrumentalize cocaine
to self-medicate cognitive impairments that can be either
preexisting or induced by chronic cocaine consumption (15,
16, 18). However, the association between cognitive impairment
and pharmacological cognitive enhancement (PCE) with cocaine
in CU has not been investigated yet. PCE has been defined as the
use of psychoactive drugs aiming at “improving cognition and
everyday performance in individuals who suffer from impaired
cognition due to brain injury or neuropsychiatric disorders” [(19),
p. 229]. Another definition—mostly employed by bioethicists—is
that “cognitive enhancement refers to the improvement of
cognitive ability in normal healthy individuals” also by
pharmacological means [(20), p. 95]. The authors prefer the
first definition, as it is broader and therefore includes self-
medication of cognitive deficits in illegal substance use populations.
Non-medical use of stimulants for PCE purposes is
sometimes practiced by healthy individuals (21, 22). In healthy
individuals, the most commonly used stimulant drug for PCE is
the medical stimulant methylphenidate (23). However, it has
been recently shown in a representative Swiss sample that also
illegal stimulants such as street amphetamine and cocaine are
used for non-medical PCE, i.e., to increase attention,
concentration and memory, even though less frequently
compared to recreational purposes (24). Nonetheless, in this
study 11.6% of participants who reported cocaine use indicated
its use for PCE (24). Importantly, street amphetamine and
cocaine as well as medical stimulants such as methylphenidate
all share vigilance- and motivation-increasing effects, which are
mediated by elevating postsynaptic catecholamine levels (23, 25).
To shed further light on the relationship between PCE and illegal
substance use, this study focuses on the illicit stimulant cocaine
and its use as a cognitive enhancer. As we have shown previously,
students reporting non-medical use of methylphenidate for PCE
purposes showed superior cognitive performances (off drug)
when compared to students not employing such strategies (26).
It could therefore also be possible that CU, who apply cocaine for
PCE, perform as well as stimulant-naïve controls or that they are
less cognitively impaired than CU without PCE motives.
There is currently little knowledge on the reasons for cocaine
use, specifically if CU employ PCE strategies in order to
compensate for their non-social and social cognitive deficits. If
this is the case, this knowledge has important implications for the
treatment of cocaine addiction as the PCE motive needs to be
addressed and alternatives to cocaine use for PCE have to be
identified and implemented. Furthermore, it is unknown if a
PCE cocaine use motive is associated with specific cognitive
deficits in comparison to stimulant-naïve controls and CU who
do not employ PCE strategies. We therefore aimed at
characterizing the cognitive profile of CU that reported using
cocaine for PCE. Specifically, we asked CU for their motives for
cocaine consumption and identified two CU subgroups. CU with
a social motive took cocaine to enhance their functioning in
social situations and CU with a cognitive motive aimed at better
performing in demanding non-social cognitive situations. We
hypothesized that CU with a social motive for cocaine
consumption have deficits in social cognition and, thus, use
cocaine for social PCE. We further expected CU with a cognitive
motive for cocaine consumption to have cognitive impairments
and thus to use cocaine for non-social PCE.
METHOD
Participants
The sample of 48 stimulant-naïve healthy controls and 42
chronic CU derives from the follow-up assessment of the
longitudinal Zurich Cocaine Cognition Study (ZuCo2St) in
which 132 individuals participated (for details please see
Supplementary Methods). Data of this sample has already
been reported in other publications from our group but with
different outcome measures or research questions (13, 15, 16,
27). General inclusion criteria at the first assessment were: age
between 18 and 60 years, German language proficiency, no
current or previous severe medical diseases, neurological
disorders or head injuries, no family history of Axis I
disorders, no current intake of medication affecting the central
nervous system and no regular cannabis consumption. Specific
inclusion criteria for CU were cocaine abuse or dependence
according to DSM-IV, cocaine as the primary used illegal drug
and a current abstinence duration of <6 months. Further
exclusion criteria for CU were history of opioid use, polytoxic
substance use and previous or current DSM-IV Axis I psychiatric
disorders with exception of cocaine, nicotine, cannabis, and
alcohol abuse/dependence, attention-deficit/hyperactivity
disorder and a previous depressive episode. Specific exclusion
criteria for controls were previous or current DSM-IV Axis I
psychiatric disorders with exception of nicotine dependence,
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regular illegal drug use (lifetime use more than 15 occasions for
each drug with exception of recreational cannabis use). The
study was approved by the Ethics Committee of the Canton
Zurich (No. E-14/2009). All participants provided written
informed consent in accordance with the Declaration of Helsinki
and received monetary compensation for their participation.
Group Assignment
Social motive group assignment: At follow-up CU filled out a
questionnaire with ten predefined motives for cocaine
consumption and indicated how often they used cocaine to
ulfill this motive on a 5-point Likert scale ranging from “never”
(1) to “always” (5). In order to identify participants with a social
motive, the mean over the three items characterizing a social
motive (“I use cocaine to go out”, “to establish contacts more
easily”, “to flirt better”) was calculated. CU were then categorized
according to a median split on the mean of the three social
motives into a social motive (SoM;Mdn > 1.83, n = 21) and a non-
social motive group (NoSoM; Mdn ≤ 1.83, n = 21).
Cognitive motive group assignment: In order to examine CU
with a cognitive motive, participants were divided according to
their rating of the item “I use cocaine to increase my
performance (e.g., at work)” into a cognitive motive group
(CoM; rating ≥ 2, n = 19) and a non-cognitive motive group
(NoCoM; rating = 1, n = 23).
Clinical and Substance Use Assessment
Trained psychologists conducted the Structured Clinical
Interview for DSM-IV Axis I disorders [SCID-I; (28)].
Additionally, participants carried out the DSM-IV self-rating
questionnaire for Axis II personality disorders [SCID-II; (29)].
Because cocaine use was linked to higher ratings on antisocial
and narcissistic personality disorder (PD) in this sample at the
baseline measurement (4), scores for antisocial and narcissistic
PD are reported here. Furthermore, participants filled out the
Beck Depression Inventory [BDI; (30)] and the Attention-
Deficit/Hyperactivity Disorder (ADHD) Self-Rating Scale
[ADHD-SR; (31)] to control for symptoms of depression and
ADHD. The Mehrfachwahl-Wortschatz-Intelligenztest (32), a
standardized German vocabulary test, was used to estimate
premorbid verbal intelligence (verbal IQ).
Subjective drug use was quantified with the standardized
Interview for Psychotropic Drug Consumption [IPDC; (33)].
Furthermore, in order to objectively assess substance use in the
time prior to the test session, hair samples were collected from all
participants and analyzed with liquid chromatography-tandem
mass spectrometry [LC-MS/MS; for details see (2)]. All
participants were asked to abstain from illegal drug use for at
least 72 h and from alcohol use 24 h prior to the assessment.
Urine toxicology screenings by means of semi-quantitative
enzyme multiplied immunoassays [for details see (2)] allowed
controlling for compliance with these instructions. Current
cocaine craving was measured with the brief version of the
Cocaine Craving Questionnaire [CCQ; (34)] and severity of
nicotine dependence was assessed with the Fagerström Test of
Nicotine Dependence (35).
Social Cognition
Multifaceted Empathy Test (MET)
The MET is a computerized test assessing cognitive (CE) and
emotional empathy by evaluating 40 photographs showing
people in different positive and negative emotional situations
(36). CE was estimated by inferring the mental state of the
depicted person by choosing the correct emotion out of four
response-alternatives. Emotional empathy was separately
evaluated by explicit emotional empathy (EEE), a rating of
participants’ empathic concern, and implicit emotional
empathy (IEE), a rating of participants’ arousal, on a 9-point
Likert scale. We calculated a global emotional empathy domain
score (EES) by averaging participants’ scores for EEE and IEE.
Movie for the Assessment of Social Cognition (MASC)
The MASC is a 15-min video-based task assessing ToM by
asking participants about the video characters’ mental states,
hence their feelings, thoughts, and intentions (37). Participants’
are presented with four response-alternatives, one representing
the correct answer and three distractors representing each three
different types of mistakes: (1) non-mental state inferences, the
situation is explained by physical causation (no-ToM), (2)
insufficient mental state inferences (undermentalizing, reduced
ToM), and (3) excessive mental state inferences (overmentalizing,
too much ToM). Based onWunderli et al. (38), we created a global
cognitive empathy domain score (CES) by averaging the MET CE
score and the number of correct answers in the MASC after z-
transforming them on the means and standard deviations of the
control group.
Cognition
In order to assess cognitive performance participants completed
the Rapid Visual Information Processing, Spatial Working Memory,
and Paired Associates Learning tasks from the Cambridge
Neuropsychological Test Automated Battery (CANTAB1) as well
as the German version of the Rey Auditory Verbal Learning Test
(39) and the Letter Number Sequencing Test (40). Following
previous publications from our group investigating cognition in
substance users (2, 15, 41, 42), 13 predefined cognitive test
parameters were incorporated into the four cognitive domains:
attention, working memory, declarative memory, and executive
functions [for details see (15, 41)] after z-transforming them on the
means and standard deviations of the control group. These four
domains were further compiled into a global cognitive index (GCI).
In order to avoid alpha-error accumulation, analyses were focused
on the four domains and the GCI.
Statistical Analysis
Statistical analyses were performed with IBM SPSS Statistics 25.0
for Windows. To assess the hypothesized deficits in social
cognition for CU of the SoM group and the hypothesized
cognitive impairments for CU of the CoM group, we
conducted analyses of covariance (ANCOVA) and included
age and verbal IQ as covariates (43). Sidak-corrected post-hoc
comparisons were carried out where appropriate. The
1http://www.cantab.com.
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significance level was set at p < 0.05 (two-tailed). Cohen’s d effect
sizes were calculated using the means and pooled standard
deviations and can be interpreted with Cohen’s convention of
small (0.2), medium (0.5), and large (0.8) effects (44). For more




Demographic Characteristics and Substance Use
Controls, NoSoM and SoM group did not significantly differ in
age and sex distribution (Table 1). However, the groups were
significantly different in years of education and verbal IQ,
indicating fewer years of education and a marginally lower
verbal IQ for the NoSoM group compared to controls and
marginally fewer years of education for the NoSoM compared
to the SoM group. Both CU groups scored significantly higher on
the BDI and ADHD-SR than controls but did not differ from
each other concerning their craving for cocaine.
CU of the SoM group have been using cocaine for a shorter
period of time (years of use) and reported less cumulated lifetime
dose of cocaine than CU of the NoSoM group (Table 1). Further
drug reports and hair analyses of both CU groups for other drugs
including alcohol revealed a clear preference for cocaine over
other substances. For more drug use details see Table S1 in the
Supplementary Material.
Social Cognition
ANCOVAs controlled for age and verbal IQ showed that controls
andCUgroupsdidnot significantlydiffer inEES (F(2, 85)=1.06,p=
.351). However, there was a significant main effect for group in the
global CES (F(2, 85) = 4.43, p = .015, Figure 1). Sidak-corrected
post-hoc comparisons revealed that the SoM group performed
significantly worse than the control group (p < .05, d = 0.65) and
on a trend-level also worse than the NoSoM group (p = .091, d =
0.60) with moderate effect sizes, respectively.
Further analyses on the individual scores of theMET andMASC
revealed that the effect in the CES was mainly driven by an inferior
performance of individuals of the SoM group in CE in the MET
(group: F(2, 85) = 6.25, p = .003, Figure 2). Sidak-corrected post-hoc
tests indicated significantly fewer correct responses for the SoM
group compared to controls (p = .020, d = 0.65) and to the NoSoM
group (p = .004, d = 0.92) with moderate and strong effect sizes,
respectively. There were no group differences for EEE and IEE (for
details seeTable S2 in the SupplementaryMaterial). AnANCOVA
controlling for age and verbal IQ did not reveal significant group
differences in the number of wrong answers in theMASC (F(2, 84) =
2.23, p= .114) but small effect sizes (d= 0.40–0.44) indicate that both
CU groups made slightly more errors in ToM than controls.
Descriptive statistics for social cognitive domain scores, MET, and
MASC can be found in Table S2 in the Supplementary Material.
As ADHD is an important covariate when analyzing
cognition and social cognition in CU (2, 4, 41), we excluded
participants with a suspected diagnosis of ADHD according to
the ADHD-SR (n = 8 CU) and repeated the analyses. Exclusion
TABLE 1 | Demographic data and cocaine use information for controls and cocaine users in the analysis of social cognitive enhancement.
Controls (n = 48) NoSoM (n = 21) SoM (n = 21) Value df/dferr p
Sex (m/f) (n) 32/16 16/5 17/4 c2 = 1.70a 2 0.427
Age 31.35 (8.73) 35.48 (9.41) 30.10 (6.52) F = 2.46b 2/87 0.092
Verbal IQ 107.58 (10.04) 101.62 (6.89)† 103.38 (11.17) F = 3.25b 2/87 0.044
Years of education 10.76 (1.83) 9.57 (1.54)* 10.71 (1.65)‡ F = 4.31c 2/44.64 0.019
ADHD-SR sum score 7.69 (5.19) 12.81 (5.99)** 14.86 (10.02)* F = 8.96c 2/35.99 0.001
BDI sum score 2.33 (3.27) 7.67 (7.54)* 8.81 (10.52)* F = 8.04c 2/29.79 0.002
Narcissistic PD 2.07 (1.68) 3.05 (2.11) 5.15 (3.22)**‡ F = 8.83c 2/33.43 0.001
Antisocial PD 2.76 (2.06) 4.15 (3.00) 4.90 (3.96) F = 3.81c 2/32.28 0.033
Cocaine
Dependence (y/n) (n) – 9/12 5/16 c2 = 1.71a 1 0.190
Times/weekg,h – 0.46 (0.00–2.50) 0.46 (0.11–2.83) U = 263.50e 0.278
Grams/weekg,h – 0.46 (0.00–11.25) 0.52 (0.13–2.67) U = 238.50e 0.650
Years of use – 11.78 (5.11) 7.56 (5.94) t = 2.47d 40 0.018
Age of onset – 24.10 (7.62) 22.60 (4.25) t = 0.79f 31.35 0.437
Last consumption (days)h – 8.00 (2.00–182.40) 5.00 (2.00–91.20) U = 171.50e 0.216
Cumulative lifetime dose (grams)h – 1,076.09 (90.87–28,103.25) 244.16 (30.42–3,361.96) U = 111.00e 0.006
Cocaine craving – 17.24 (10.05) 19.00 (9.61) t = −0.58d 40 0.565




– 10,155.00 (1,253–290,250) 5,010.00 (908–64,750) U = 146.00e 0.061
Cocaineh – 8,050.00 (1,110–200,000) 4,200.00 (790–59,500) U = 148.00e 0.068
Benzoylecgonineh – 1,950.00 (125–84,000) 670.00 (100–9,750) U = 133.00e 0.028
Norcocaineh – 210.00 (18–6,250) 90.00 (13–725) U = 133.00e 0.028
Cocaethyleneh – 340.00 (0–9,200) 205.00 (0–5,000) U = 196.00e 0.538
Significant p-values are shown in bold. Means and standard deviation of means in parenthesis. ADHD-SR, ADHD self-rating scale; BDI, Beck Depression Inventory. ac2 test (across all
groups/cocaine users only) for frequency data. bANOVA (across all groups, with Sidak post-hoc tests vs. controls: †p < 0.10). cWelch’s ANOVA (across all groups, with Games-Howell
post-hoc tests vs. controls: *p < 0.05; **p < 0.01; vs. NoSoM: ‡p < 0.10). dIndependent t-test (cocaine users only). eMann–Whitney U test (cocaine users only). fWelch’s t-test (cocaine
users only). gAverage use during the last six months. hMedian (range) is reported. iCocainetotal (= cocaine + benzoylecgonine + norcocaine) as a more robust parameter (45).
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of CU with ADHD altered the result for the global CES as this
effect no longer remained significant. However, the effect for CE
in the MET persisted even after exclusion of subjects with
ADHD. Furthermore, to exclude the possibility that our
findings were driven by more cumulated lifetime cocaine
consumption (2, 15, 16) in the SoM group, we repeated the
ANCOVAs adjusted for age and verbal IQ for the domain, the
MET, and the MASC scores only comparing CU groups and
additionally included ln-transformed cumulated lifetime dose of
cocaine. This did not change the results. In an exploratory
analysis, we additionally investigated the performance in the
neurocognitive domains in the social cognitive enhancement
groups. These results can be found in Table S2 in the
Supplementary Material.
Non-Social Cognitive Enhancement
Demographic Characteristics and Substance Use
Controls and CU of the NoCoM and CoM group did not
significantly differ in age, sex distribution, and years of
education (Table 2). However, the groups were significantly
different in verbal IQ, indicating a marginally lower IQ for the
CoM group compared to controls. Both CU groups scored
significantly higher on the BDI and ADHD-SR than controls but
did not differ from each other concerning their craving for cocaine.
TheCUgroups showedsimilar patternsof cocaineuse (Table2).
However, the CoM group indicated higher consumption frequency
per week. Drug reports and hair analyses for both CU groups again
confirmed a clear preference for cocaine over other substances. For
more details see Table S3.
Cognition
ANCOVAs controlled for age and verbal IQ revealed significant
group effects in the GCI (F(2, 85) = 4.63, p = .012, Figure 3) and
the domains working memory (F(2, 85) = 6.76, p = .002),
declarative memory (F(2, 85) = 3.18, p = .047), and executive
functions (F(2, 85) = 4.13, p = .002). No significant effect was
found for attention (F(2, 85) = 0.73, p = .485). Sidak-corrected
post-hoc comparisons for the GCI demonstrated that only the
CoM group performed significantly worse than controls (p =
.034; d = 0.60). The effect for the NoCoM group was only
marginally significant (p = .059; d = 0.52). However, both
effects had moderate effect sizes indicating cognitive deficits in
CU in general. Regarding the working memory domain, both,
the CoM (p = .004; d = 0.84) and NoCoM group (p = .037; d =
0.61), performed worse than controls, with the CoM group
showing a strong, and the NoCoM group showing a moderate
effect size. Concerning declarative memory, only the CoM group
showed inferior performance compared to controls (p = .048, d =
0.60), whereas the NoCoM group showed weaker performance in
executive functions (p = .015; d = 0.67). Both effects had a
moderate effect size. Analyses of the individual test parameters
underlying the cognitive domains are presented in Table S4.
We again excluded subjects with a suspected ADHD and
repeated ANCOVAs on the GCI and the cognitive domains.
However, this did not change the overall results. We also repeated
the analyses only with CU and included ln-transformed cumulated
lifetime dose of cocaine. This again did not change the results. In an
exploratory analysis, we analyzed social cognition in the non-social
cognitive enhancement groups. Results can be found inTable S5 in
the Supplementary Material.
DISCUSSION
We investigated the cognitive profile of CU with a social motive
who occasionally take cocaine to enhance their performance in
social situations and CU with a cognitive motive who at least
FIGURE 1 | Mean z-scores and standard errors for the Cognitive Empathy
Score (CES) in controls and cocaine users with (SoM) and without a social
enhancement motive (NoSoM). Values adjusted for verbal IQ and age. Sidak
post-hoc tests vs. controls: *p < 0.05; vs. NoSoM: †p < 0.10. Cohen’s d
effect sizes for group comparisons are shown on top of the bars.
FIGURE 2 | Mean correct responses and standard errors for cognitive empathy
in the Multifaceted Empathy Test (MET) of controls and cocaine users with (SoM)
and without a social enhancement motive (NoSoM). Values adjusted for verbal IQ
and age. Sidak post-hoc tests vs. controls: *p < 0.05; vs. NoSoM: °°p < 0.01.
Cohen’s d effect sizes for group comparisons are shown on top of the bars.
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sometimes take cocaine to perform better in demanding
cognitive situations, e.g., at work.
First, socially motivated CU showed lower cognitive empathy
(as reflected by the CES) compared to controls (d = 0.65) and, on
a trend-level, also compared to CU of the NoSoM group (d =
0.60). The lower score in the CES for the SoM group was mainly
driven by reduced cognitive empathy in the MET. We therefore
propose that CU with a social motive for cocaine consumption
use cocaine partially to counteract deficits in the cognitive aspect
of empathy. Contrary to the baseline measurement of this
sample, we did not find impairments in emotional empathy in
the same test (4). Notably, cocaine hair concentrations indicate
that the follow-up sample (analyzed here) did not include as
many severe users as the baseline sample [compare with (2, 4)]
TABLE 2 | Demographic data and cocaine use information for controls and cocaine users in the analysis of non-social cognitive enhancement.
Controls (n = 48) NoCoM (n = 23) CoM (n = 19) Value df/dferr p
Sex (m/f) (n) 32/16 18/5 15/4 c2 = 1.59a 2 0.453
Age 31.35 (8.73) 34.61 (9.89) 30.58 (5.79) F = 1.48b 2/87 0.234
Verbal IQ 107.58 (10.04) 103.04 (7.83) 101.84 (10.84)† F = 3.15b 2/87 0.048
Years of education 10.76 (1.83) 10.04 (1.72) 10.26 (1.66) F = 1.45b 2/87 0.240
ADHD-SR sum score 7.69 (5.19) 13.83 (6.64)** 13.84 (10.00)* F = 9.42c 2/34.38 0.001
BDI sum score 2.33 (3.27) 8.57 (9.43)* 7.84 (8.82)* F = 7.68c 2/29.20 0.002
Narcissistic PD 2.07 (1.68) 3.96 (2.51)** 4.29 (3.41)* F = 7.58c 2/30.71 0.002
Antisocial PD 2.76 (2.06) 4.61 (3.45)† 4.41 (3.64) F = 3.82c 2/30.78 0.033
Cocaine
Dependence (y/n) (n) – 6/17 8/11 c2 = 1.20a 1 0.273
Times/weekg,h – 0.46 (0.04–1.50) 0.69 (0.00–2.83) U = 302.00e 0.034
Grams/weekg,h – 0.46 (0.06–2.00) 0.81 (0.00–11.25) U = 283.50e 0.100
Years of use – 11.17 (5.96) 7.86 (5.38) t = 1.87f 40 0.069
Age of onset – 23.95 (7.12) 22.61 (4.79) t = 0.70f 40 0.489
Last consumption (days)h – 8.00 (2.00–121.60) 5.00 (2.50–182.40) U = 161.00e 0.145
Cumulative lifetime dose (grams)h – 633.26 (30.42–28,103.25) 360.20 (36.41–6,603.22) U = 208.00e 0.791
Cocaine craving – 15.26 (5.60) 21.58 (12.46) t = -2.05f 23.967 0.052




– 5,340.00 (953–290,250) 7,390.00 (908–202,035) U = 235.00e 0.677
Cocaineh – 4,500.00 (790–200,000) 6,000.00 (790–170,000) U = 241.00e 0.570
Benzoylecgonineh – 1,050.00 (115–84,000) 875.00 (100–31,000) U = 224.00e 0.889
Norcocaineh – 135.00 (13–6,250) 150.00 (15–1,035) U = 208.50e 0.800
Cocaethyleneh – 305.00 (0–9,200) 170.00 (0–8,550) U = 178.00e 0.306
Significant p-values are shown in bold. Means and standard deviation of means in parenthesis. ADHD-SR, ADHD self-rating scale; BDI, Beck Depression Inventory. ac2 test (across all
groups/cocaine users only) for frequency data. bANOVA (across all groups, with Sidak post-hoc tests vs. controls: †p < 0.10). cWelch’s ANOVA (across all groups, with Games–Howell
post-hoc tests vs. controls: *p < 0.05; **p < 0.01). dWelch’s t-test (cocaine users only). eMann–Whitney U test (cocaine users only). fIndependent t-test (cocaine users only). gAverage use
during the last six months. hMedian (range) is reported. iCocainetotal (= cocaine + benzoylecgonine + norcocaine) as a more robust parameter (45).
FIGURE 3 | Mean z-scores and standard errors for the four cognitive domains and the Global Cognitive Index (GCI) of controls and cocaine users with (CoM) and
without a cognitive enhancement motive (NoCoM). Values adjusted for verbal IQ and age. Sidak post-hoc tests vs. controls: †p < 0.10; *p < 0.05; **p < 0.01.
Cohen’s d effect sizes for group comparisons are shown on top of the bars.
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due to a higher drop-out rate within the more severe users.
Moreover, although we excluded abstinent (n = 7) and non-
chronic CU (cocaine hair concentration <500 pg/mg, n = 14) at
follow-up, the sample still included CU who decreased their
cocaine consumption over one year accompanied with improved
cognition at follow-up (15, 16). This might explain a lack of
findings regarding emotional empathy. Emotional empathy
deficits seem to be at least partially drug-induced (16).
However, this does not seem to be the case for cognitive
empathy and socially motivated CU. Within CU, the inclusion
of self-reported cumulated lifetime dose of cocaine did not change
the results in social cognition suggesting that these deficits might
precede stimulant use. Moreover, the SoM group reported
significantly less (Mdn = 244.2 g) cumulated lifetime dose of
cocaine than the NoSoM group (Mdn = 1,076.1 g), additionally
supporting that the effect found for cognitive empathy is maybe
not induced by previous cocaine use. However, this needs to be
verified in further longitudinal studies. Interestingly, Maier et al.
(26) examined methylphenidate users that took methylphenidate
for PCE and found reduced cognitive empathy on the MET as
well, which points to a potential common underlying factor in
stimulant users that use the substances for PCE.
Second, we found non-social cognitive impairments in both CU
groups as indicated by the GCI, although the comparison between
controls and the NoCoM group was only marginally significant (d =
0.52). This replicates results from previous studies (1, 5–7) and the
baseline measurement (2), although effects were somewhat stronger
at the baseline assessment. Both CU groups showed impairments in
working memory. However, only CU of the CoM group had
additional deficits in declarative memory, whereas only CU of the
NoCoM group demonstrated deficits in executive functions. In both
cases, the respective other CU group displayed intermediate
performance but was not significantly different from either
controls or the other CU group. Surprisingly, no differences were
found for attention. However, as mentioned before, the follow-up
sample was—in the mean—less severely addicted compared to the
baseline sample. Given the significant correlation between cognition
and cocaine use intensity (2), this likely explains the overall smaller
effects in cognition in the present sample of CU. Based on our
findings, we propose that CU with a cognitive motive for cocaine
consumption use cocaine at least sometimes to counteract deficits,
e.g., in working memory functions. Interestingly, they show
intermediate performance in executive functions, suggesting that
they are likely not (yet) as impaired in this domain as CU without a
cognitive motive. This is not surprising as PCE is considered a
complex goal-oriented behavior (46). In order to use a substance for
PCE, one needs to be able to plan this behavior to get the best
outcome. Remarkably, Maier et al. (26) actually found superior
functioning of PCE motivated methylphenidate users in executive
functions and goal-directed decision-making which points in the
same direction. Of note, this study used exactly the same cognitive
test battery as applied here.
Additional analyses after exclusion of subjects with a putative
diagnosis of ADHD did not change the overall results in
cognition whereas some changes occurred for social cognition
as the effect in the CES did not remain significant. This is not
surprising as we did not observe strong effects in the MASC at
baseline (4) where the effect was, additionally, partially driven by
individuals with a suspected ADHD diagnosis (41). However, the
effect on the cognitive empathy score of the MET persisted. After
exclusion of subjects with ADHD, the respective effects in the
MET and MASC canceled each other out leading to a non-
significant result in the composite score. Nevertheless, we believe
that our main results are still valid and meaningful even without
considering ADHD, as the motive to enhance social and non-
social cognitive performance through cocaine consumption
needs to be considered within the entire profile of the CU and
often, cocaine use is associated with an ADHD diagnosis (2, 15,
41, 47–49). Notably, CU with ADHD (n = 8) appeared more
frequently in the enhancement groups with seven CU with
ADHD in the SoM (p < .001, Fisher’s exact test) and six in the
CoM group (p < .001, Fisher’s exact test) indicating the use of
cocaine as a form of self-medication especially for those CU with
a putative comorbid ADHD.
The findings need to be interpreted with the following
limitations in mind. First, controls, NoSoM and SoM groups
differed with regard to verbal IQ and years of education and
controls and CoM group differed with regard to verbal IQ.
However, groups were matched for age and sex and we
included age and verbal IQ as covariates in the statistical
models. We did not include years of education as a covariate
as only verbal IQ differed in both investigations and verbal IQ
and years of education were moderately correlated with each
other (r = 0.31, p < .01). Second, sample sizes of the CU groups
were small and only a few CU utilized cocaine intensively as a
social or cognitive enhancer. Therefore, the results need to be
replicated in larger samples of CU who instrumentalize cocaine
for PCE more regularly.
This study demonstrates that a subgroup of CU who
sometimes employ PCE strategies also show social and non-
social cognitive deficits. It is therefore conceivable, that these
subgroups try to compensate cognitive deficits with cocaine use.
This instrumentalization of cocaine use can be considered as a
self-medication of pre-existing or cocaine-induced cognitive
impairments (or both), which seems to be especially true for
CU with a co-morbid ADHD diagnosis. Consequently, existing
PCE strategies have important implications for treatment
outcomes as these strategies need to be addressed and
alternatives to satisfy the motive need to be found. In general,
social and non-social cognitive impairments have been proposed
to diminish the efficacy of therapeutic interventions (50, 51).
Thus, psychotherapeutic but also psychopharmacological
approaches were recently suggested to alleviate cognitive
deficits in CU in order to improve addiction therapy success
(51–53). For instance, cognitive enhancement with ADHD (or
other) medications has been proposed as a treatment target for
cognitive disturbances in cocaine use disorder in the past (53–
55). However, contrary to opioid or nicotine dependence,
substitution in cocaine use disorder is not yet approved due to
unclear evidence from clinical studies (56–58). Nevertheless,
substitution with methylphenidate has been proposed to be a
safe and effective treatment in CU with comorbid ADHD (57).
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As our findings indicate that especially CU with comorbid
ADHD employ PCE strategies and that cognitive impairments
in CU with ADHD are amplified (41), we assume that
substitution could be beneficial in these patients. We therefore
suggest that attending physicians discuss putative PCE strategies
and cognitive impairments with their patients in general, explain
the negative long-term consequences of cocaine use (15, 16, 18)
and additionally offer PCE with medical drugs as an alternative
to CU with comorbid ADHD. This could foster treatment
compliance as patients are signaled that their personal goals in
using cocaine are respected and met. However, the use of medical
stimulants might delay recovery that can be observed after longer
periods of abstinence as the reversibility of cocaine-induced
cognitive dysfunctions has been proposed to reflect re-
adaptation of brain functions and neurotransmitter systems (15).
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the Ethics Committee of the Canton Zurich. The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
BQ and A-KK had full access to all the data in the study and take
responsibility for the integrity of the data and the accuracy of the
data analysis. BQ developed the study concept and design. MV,
KP, and LH contributed to the acquisition of the data, A-KK and
BQ analyzed and interpreted the data. A-KK and BQ drafted the
manuscript. All authors contributed to the article and approved
the submitted version. ES and BQ obtained funding. MV, KP,
LH, and ES contributed to the administrative, technical, or
material support. ES and BQ were in charge of supervision.
FUNDING
The study was supported by grants from the Swiss National
Science Foundation (Grant Nos. PP00P1-123516/1 and PP00P1-
146326/1) and the Olga Mayenfisch Foundation. A-KK was
financed by a grant of the Swiss National Science Foundation
(105319_162639) to BQ. The funders had no role in study
design; collection, management, analysis, and interpretation of
the data; preparation, review, and approval of the manuscript,
and the decision to submit the manuscript for publication.
ACKNOWLEDGMENTS
We are grateful to Daniela Jenni, Kathrin Küpel, and Franziska
Minder for their excellent support with recruitment and
assessment of the participants.
SUPPLEMENTARY MATERIAL




1. Jovanovski D, Erb S, Zakzanis KK. Neurocognitive deficits in cocaine users: A
quantitative review of the evidence. J Clin Exp Neuropsychol (2005) 27:189–
204. doi: 10.1080/13803390490515694
2. Vonmoos M, Hulka LM, Preller KH, Jenni D, Baumgartner MR, Stohler R,
et al. Cognitive dysfunctions in recreational and dependent cocaine users:
Role of attention-deficit hyperactivity disorder, craving and early age at onset.
Br J Psychiatry (2013) 203:35–43. doi: 10.1192/bjp.bp.112.118091
3. Hulka LM, Eisenegger C, Preller KH, Vonmoos M, Jenni D, Bendrick K, et al.
Altered social and non-social decision-making in recreational and dependent
cocaine users. Psychol Med (2014) 44:1015–28. doi: 10.1017/S0033291713001839
4. Preller KH, Hulka LM, Vonmoos M, Jenni D, Baumgartner MR, Seifritz E,
et al. Impaired emotional empathy and related social network deficits in
cocaine users. Addict Biol (2014) 19:452–66. doi: 10.1111/adb.12070
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J. Features and prevalence of patients with probable adult attention deficit
hyperactivity disorder who request treatment for cocaine use disorders.
Psychiatry Res (2011) 185:205–10. doi: 10.1016/j.psychres.2009.03.019
49. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F,
Crunelle CL, SwetsM, et al. Prevalence of attention-deficit hyperactivity disorder in
substance use disorder patients: A meta-analysis and meta-regression analysis.
Drug Alcohol Depend (2012) 122:11–9. doi: 10.1016/j.drugalcdep.2011.12.007
50. Quednow BB. Social cognition and interaction in stimulant use disorders.
Curr Opin Behav Sci (2017) 13:55–62. doi: 10.1016/j.cobeha.2016.10.001
51. Rezapour T, Hatami J, Farhoudian A, Sofuoglu M, Noroozi A, Daneshmand R,
et al. Neuro cognitive rehabilitation for disease of addiction (NECOREDA)
program: from development to trial. Basic Clin Neurosci (2015) 6:291–8.
52. Aharonovich E, Hasin DS, Nunes EV, Stohl M, Cannizzaro D, Sarvet A, et al.
Modified cognitive behavioral therapy (M-CBT) for cocaine dependence:
Development of treatment for cognitively impaired users and results from a
Stage 1 trial. Psychol Addict Behav (2018) 32:800–11. doi: 10.1037/adb0000398
53. Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a
treatment for drug addictions. Neuropharmacology (2013) 64:452–63.
doi: 10.1016/j.neuropharm.2012.06.021
Kexel et al. Cognitive Enhancement in Cocaine Users
Frontiers in Psychiatry | www.frontiersin.org June 2020 | Volume 11 | Article 6189
54. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant
addiction. Addiction (2010) 105:38–48. doi: 10.1111/j.1360-0443.2009.02791.x
55. Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive function as a
transdiagnostic treatment target in stimulant use disorders. J Dual Diagn
(2016) 12:90–106. doi: 10.1080/15504263.2016.1146383
56. Quednow BB, Herdener M. Human pharmacology for addiction medicine:
From evidence to clinical recommendations. In: Ekhtiari H, Paulus MP, editors.
Progress in Brain Research. Amsterdam, Netherlands: Elsevier (2016). p. 227–50.
doi: 10.1016/bs.pbr.2015.07.017
57. Dürsteler K, Berger E-M, Strasser J, Caflisch C, Mutschler J, Herdener M, et al.
Clinical potential of methylphenidate in the treatment of cocaine addiction: a
review of the current evidence. Subst Abuse Rehabil (2015) 6:61–74. doi: 10.2147/
SAR.S50807
58. Lingford-Hughes A, Welch S, Peters L, Nutt D. BAP updated guidelines:
evidence-based guidelines for the pharmacological management of substance
abuse, harmful use, addiction and comorbidity: recommendations from BAP.
J Psychopharmacol (2012) 26:899–952. doi: 10.1177/0269881112444324
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Kexel, Vonmoos, Preller, Hulka, Seifritz and Quednow. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Kexel et al. Cognitive Enhancement in Cocaine Users





1. Supplementary Methods 
Methods S1. Recruitment and participant selection. 
Participants were recruited at the baseline assessment of the longitudinal Zurich Cocaine 
Cognition Study (ZuCo2St) through drug prevention and treatment centers, psychiatric hospitals, 
advertisements in local newspapers, online media, and word of mouth. 
132 participants (79 cocaine users, 53 controls) participated in the follow-up assessment of the 
longitudinal ZuCo2St. Of these, 21 subjects (16 cocaine users, 5 controls) were excluded due to the use 
of illegal substances, objectively verified by hair analyses, that were not allowed by our exclusion 
criteria (e.g., opioids or excessive MDMA consumption) or beginning of intake of psychotropic 
medication (e.g., antipsychotics or antidepressants). Furthermore, additional 21 cocaine users whose 
hair concentration of cocaine was below cut-off (< 500 pg/mg) were excluded to ensure that only 




Methods S2. Statistical analysis. 
Demographic and substance use data were analyzed by means of Pearson’s χ2-test and analyses 
of variance (ANOVA) followed by Sidak-corrected post-hoc comparisons where appropriate. If data 
were not normally distributed or the homogeneity of variance assumption was violated, the Kruskal-
Wallis-test with Bonferroni-corrected post-hoc comparisons and Welch’s ANOVA with Games-
Howell-corrected post-hoc comparisons were carried out, respectively. Analyses for CU only were 
either implemented with independent t-tests or, if data were non-normally distributed or showed 
heterogeneity of variance, with Mann-Whitney U-test or Welch’s t-test, respectively. 
Due to the highly skewed distribution of cumulated lifetime cocaine dose (Shapiro-Wilk 
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2. Supplementary Tables 
Table S1. Pattern and amount of substance use for controls and cocaine users in the analysis of social cognitive enhancement. 
 Controls (n = 48) NoSoM (n = 21) SoM (n = 21) Value df/dferr p 
Nicotine       
Smoking (n) 40 18 17 χ2 = 0.17a 2 0.918 
Cigarettes per 
dayg, h 
9.85 (8.69) 13.39 (7.09) 16.00 (10.99) F = 3.09b 2/72 0.052 
Years of useh 12.02 (8.18) 17.69 (7.86)* 12.45 (5.28) F = 3.70b 2/72 0.030 
FTND sum scoreh 1.93 (2.39) 4.29 (2.37)** 4.25 (2.54)** F = 8.52b 2/70 <0.001 
       
Alcohol       
Grams/weekg 104.35 (88.58) 210.62 (240.02) 196.92 (165.09)† F = 4.43c 2/31.17 0.020 
Years of use 14.00 (8.68) 16.16 (7.09) 12.79 (6.11) F = 1.02b 2/87 0.364 
       
Cannabis       
Grams/weekg, i 0.00 (0.00 – 10.00) 0.00 (0.00 – 20.00) 0.17 (0.00 – 10.00) H = 5.40d 2 0.067 




(0.50 – 2737.35) 
5.00 
(0.13 – 212.80) 
3.75 
(0.50 – 182.40) 




(0.00 – 27555.00) 
836.63 
(0.00 – 27789.36) 
728.45 
(0.00 – 9705.06)† 
H = 6.63d 2 0.036 
Urine toxicology 
(neg/pos) 
42/6 14/7 10/11 χ2 = 12.50a 2 0.002 
       
Amphetamines       
Grams/weekg, i – 0.00 (0.00 – 0.81) 0.00 (0.00 – 0.35) U = 225.00e  0.875 
Years of usei 0.00 
(0.00 – 3.00) 
0.00 
(0.00 – 13.00) 
2.50 
(0.00 – 17.00)*** 
H = 26.31d 2 <0.001 
Last consumption 
(days) 




(0.00 – 0.65) 
0.00 
(0.00 – 782.15)** 
2.40 
(0.00 – 260.70)***°° 
H = 33.83d 2 <0.001 
Hair sample 
(pg/mg)i 
– 0.00 (0.00 – 1090) 0.00 (0 – 2000) U = 247.00e  0.389 
       
MDMA       
Pills/weekg, i 0.00 
(0.00 – 0.06) 
0.00 
(0.00 – 2.07) 
0.00 
(0.00 – 3.50)***° 
H = 22.18d 2 <0.001 
 
3 
Years of usei 0.00 
(0.00 – 10.00) 
0.00 
(0.00 – 15.00)* 
3.00 
(0.00 – 19.00)*** 




(60.80 – 364.98) 
106.40 
(14.00 – 364.81) 
25.71 
(4.00 – 290.60) 




(0.00 – 22.00) 
2.50 
(0.00 – 876.87)** 
17.05 
(0.00 – 580.41)*** 
H = 30.50d 2 <0.001 
Hair sample 
(pg/mg)i 
0.00 (0 – 143) 0.00 (0 – 20500) 80.00 (0 – 6500)***° H = 31.29d 2 <0.001 
       
GHB       
Cumulative lifetime 
dose (pipettes)i 
– 0.00 (0.00 – 2.00) 0.00 (0.00 – 79.00) U = 221.00e  0.988 
       




(0.00 – 10.00) 
1.00 
(0.00 – 324.50)* 
4.50 
(0.00 – 55.00)*** 
H = 18.87d 2 <0.001 
Significant p-values are shown in bold. Means and standard deviation of means in parenthesis. Abbreviations: FTND: Fagerström Test of 
Nicotine Dependence. a χ2 test (across all groups/cocaine users only) for frequency data. b ANOVA (across all groups, with Sidak post-hoc 
tests vs. controls: *p<0.05; **p<0.01). c Welch’s ANOVA (across all groups, with Games-Howell post-hoc tests vs. controls: †p<0.10; 
**p<0.01). d Kruskal-Wallis Test (with Bonferroni post-hoc tests vs. controls: †p<0.10; *p<0.05; **p<0.01; ***p<0.001; vs. NoSoM: °p<0.05; 
°°p<0.01). e Mann-Whitney-U-Test (cocaine users only). f Welch test (cocaine users only). g Average use during the last six months. h Only 
smokers. i Median (range) is reported. 
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Table S2. Social and general cognition data in the analysis of social cognitive enhancement. 
 Controls (n = 48) NoSoM (n = 21) SoM (n = 21) F df/dferr p 
Social cognitive domains       
Emotional empathy score 5.22 (0.22) 4.86 (0.35) 4.65 (0.33) 1.06 2/85 0.351 
Cognitive empathy score -0.11 (0.11) -0.17 (0.18) -0.70 (0.17)*‡ 4.43 2/85 0.015 
       
MET       
Explicit emotional empathy 5.36 (0.23) 5.11 (0.35) 4.80 (0.34) 0.96 2/85 0.387 
Implicit emotional empathy 5.07 (0.23) 4.62 (0.35) 4.51 (0.34) 1.15 2/85 0.322 
Cognitive empathy 25.43 (0.54) 26.64 (0.84) 22.71 (0.81)*°° 6.25 2/85 0.003 
       
MASC       
ToM total errorsa 8.83 (0.55) 10.74 (0.86) 10.40 (0.82) 2.23 2/84 0.114 
       
Cognitive domains       
Attention -0.13 (0.12) -0.51 (0.18) -0.17 (0.17) 1.59 2/85 0.211 
Working memory -0.07 (0.10) -0.71 (0.16)** -0.54 (0.15)* 6.72 2/85 0.002 
Declarative memory -0.09 (0.17) -0.88 (0.26)* -0.48 (0.25) 3.28 2/85 0.043 
Executive functions -0.09 (0.12) -0.70 (0.18)* -0.35 (0.17) 3.84 2/85 0.025 
Global cognitive index -0.09 (0.10) -0.70 (0.15)** -0.39 (0.14) 5.87 2/85 0.004 
Significant p-values are shown in bold. Means and standard error of the mean in parenthesis. Adjusted for verbal IQ and age. Sidak post-hoc 





Table S3. Pattern and amount of substance use for controls and cocaine users in the analysis of non-social cognitive enhancement. 
 Controls (n = 48) NoCoM (n = 23) CoM (n = 19) Value df/dferr p 
Nicotine       
Smoking (n) 40 19 16 χ2 = 0.02a 2 0.990 
Cigarettes per  
dayf, g 
9.85 (8.69) 14.73 (6.23) 14.57 (11.97) F = 2.69b 2/72 0.075 
Years of useg 12.02 (8.18) 15.88 (8.21)* 14.28 (5.78) F = 1.70b 2/72 0.190 
FTND sum scoreg 1.93 (2.39) 4.32 (2.34)** 4.21 (2.61)** F = 8.53b 2/70 <0.001 
       
Alcohol       
Grams/weekf 104.35 (88.58) 215.78 (228.99)† 189.24 (172.94) F = 4.19c 2/30.75 0.025 
Years of use 14.00 (8.68) 15.38 (8.07) 13.39 (4.69) F = 0.38b 2/87 0.687 
       
Cannabis       
Grams/weekf, h 0.00 
(0.00 – 10.00) 
0.00 
(0.00 – 5.00) 
0.38 
(0.00 – 20.00)**° 
H = 10.48d 2 0.005 




(0.50 – 2737.35) 
5.00 
(1.00 – 91.20) 
3.75 
(0.13 – 212.80) 




(0.00 – 27555.00) 
219.60 
(0.00 – 27789.36) 
1322.20 
(0.00 – 24809.85)** 
H = 9.98d 2 0.007 
Urine toxicology 
(neg/pos) 
42/6 16/7 8/11 χ2 = 14.57a 2 0.001 
       
Amphetamines       
Grams/weekf, h – 0.00 (0.00 – 0.81) 0.00 (0.00 – 0.35) U = 232.00e  0.634 
Years of useh 0.00 
(0.00 – 3.00) 
0.00 
(0.00 – 13.00) 
1.17 
(0.00 – 17.00)*** 




(4.00 – 273.60) 
25.70 
(4.00 – 364.98) 




(0.00 – 0.65) 
0.10 
(0.00 – 104.28)* 
3.27 
(0.00 – 782.15)** 
H = 34.16d 2 <0.001 
Hair sample 
(pg/mg)h 
– 0.00 (0 – 1090) 0.00 (0 – 2000) U = 260.00e  0.175 
       
MDMA       
Pills/weekf, h 0.00 
(0.00 – 0.06) 
0.00 
(0.00 – 2.07)† 
0.00 
(0.00 – 3.50)*** 
H = 17.34d 2 <0.001 
Years of useh 0.00 
(0.00 – 10.00) 
0.00 
(0.00 – 15.00)* 
3.50 
(0.00 – 19.00)*** 
H = 23.89d 2 <0.001 





(60.80 – 364.98) 
24.50 
(11.00 – 364.81) 
121.60 
(4.00 – 212.80) 




(0.00 – 22.00) 
1.12 
(0.00 – 580.41)* 
18.00 
(0.00 – 876.87)** 
H = 31.06d 2 <0.001 
Hair sample 
(pg/mg)h 
0.00 (0 – 143) 0.00 (0 – 20500)** 35.00 (0 – 6500)*** H = 25.08d 2 <0.001 
       
GHB       
Cumulative lifetime 
dose (pipettes)h 
– 0.00 (0.00 – 2.00) 1.00 (0.00 – 79.00) U = 309.00e  0.005 
       




(0.00 – 10.00) 
1.00 
(0.00 – 55.14)† 
4.50 
(0.00 – 324.50)***‡ 
H = 21.47d 2 <0.001 
Significant p-values are shown in bold. Means and standard deviation of means in parenthesis. Abbrevations: FTND: Fagerström Test of 
Nicotine Dependence. a χ2 test (across all groups/cocaine users only) for frequency data. b ANOVA (across all groups, with Sidak post-hoc 
tests vs. controls: *p<0.05; **p<0.01). c Welch’s ANOVA (across all groups, with Games-Howell post-hoc tests vs. controls: †p<0.10). d 
Kruskal-Wallis Test (with Bonferroni post-hoc tests vs. controls: †p<0.10; *p<0.05; **p<0.01; ***p<0.001; vs. NoCoM: ‡p<0.10; °p<0.05). 





Table S4. Scores of neuropsychological tests. 
 Controls (n = 48) NoCoM (n = 23) CoM (n = 19) Fa df/dferr p 
Attention       
RVP Discrimination performance A‘ 0.93 (0.01) 0.92 (0.01) 0.92 (0.01) 0.63 2/85 0.537 
RVP Total hits 19.33 (0.59) 18.77 (0.86) 18.23 (0.94) 0.51 2/85 0.605 
RAVLT Supraspan trial 1b 9.53 (0.33) 8.95 (0.47) 8.95 (0.51) 0.71 2/84 0.496 
       
Working memory       
LNST Score 15.43 (0.41) 14.32 (0.59) 13.23 (0.64)* 4.33 2/85 0.016 
SWM Total errors 14.47 (2.24) 25.60 (3.24)* 24.72 (3.53)† 5.13 2/85 0.008 
PAL First trial memory score 16.17 (0.45) 15.38 (0.65) 14.63 (0.71) 1.76 2/85 0.179 
       
Declarative memory       
RAVLT Learning performance 
(∑trial 1-5)1 
63.82 (1.19) 59.50 (1.71) 59.35 (1.86) 3.05 2/84 0.052 
RAVLT Adjusted recognition p(A)b 0.86 (0.02) 0.85 (0.03) 0.83 (0.03) 0.36 2/84 0.701 
RAVLT Delayed recall trial 7b 13.51 (0.36) 12.88 (0.52) 12.03 (0.56) 2.42 2/84 0.095 
PAL Total errors adjusted 7.97 (1.91) 12.84 (2.77) 16.90 (3.01)* 3.27 2/85 0.043 
PAL Total trials adjusted 8.14 (0.43) 8.57 (0.62) 9.74 (0.67) 1.97 2/85 0.146 
       
Executive functions       
SWM Strategy score 30.12 (0.81) 32.75 (1.17) 30.70 (1.28) 1.67 2/85 0.194 
RAVLT Recall consistency (%)b 93.01 (1.17) 87.99 (1.67) 90.75 (1.83) 2.95 2/84 0.058 
Significant p-values are shown in bold. Means and standard error of the mean in parenthesis. Adjusted for verbal IQ and age. Abbreviations: 
RVP: Rapid Visual Information Processing; RAVLT: Rey Auditory Verbal Learning Test; LNST: Letter Number Sequencing Test; SWM: 
Spatial Working Memory; PAL: Paired Associates Learning. a ANCOVA (across all groups, with Sidak post-hoc tests vs. controls: †p<0.10; 
*p<0.05). b In the RAVLT, data is missing for one control subject. 
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Table S5. Social cognition data in the analysis of non-social cognitive enhancement. 
 Controls (n = 48) NoCoM (n = 23) CoM (n = 19) F df/dferr p 
Social cognitive domains       
Emotional empathy score 5.21 (0.21) 5.33 (0.31) 4.08 (0.34)*° 4.79 2/85 0.011 
Cognitive empathy score -0.10 (0.12) -0.25 (0.17) -0.67 (0.18)* 3.44 2/85 0.037 
       
MET       
Explicit emotional empathy 5.36 (0.22) 5.50 (0.32) 4.29 (0.34)*° 4.21 2/85 0.018 
Implicit emotional empathy 5.07 (0.22) 5.15 (0.32) 3.86 (0.34)*° 5.05 2/85 0.008 
Cognitive empathy 25.49 (0.56) 25.89 (0.81) 23.06 (0.88)†‡ 3.42 2/85 0.037 
       
MASC       
ToM total errors 8.84 (0.55) 10.58 (0.81) 10.53 (0.86) 2.19 2/84 0.118 
Significant p-values are shown in bold. Means and standard error of the mean in parenthesis. Adjusted for verbal IQ and age. Sidak post-hoc 
tests vs. controls: †p<0.10; *p<0.05; vs. NoCoM: ‡p<0.10; °p<0.05. 
 
 
